307 related articles for article (PubMed ID: 22830776)
21. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
Behr TM; Béhé M; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
[TBL] [Abstract][Full Text] [Related]
22. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
[TBL] [Abstract][Full Text] [Related]
24. The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study.
Ljungberg M; Sjögreen-Gleisner K
Acta Oncol; 2011 Aug; 50(6):981-9. PubMed ID: 21767200
[TBL] [Abstract][Full Text] [Related]
25. Internal dose to active marrow and endosteum from radioactive iodine.
Hoseinian-Azghadi E; Rafat-Motavalli L; Miri-Hakimabad H
Radiat Prot Dosimetry; 2015 Apr; 164(3):291-7. PubMed ID: 25157198
[TBL] [Abstract][Full Text] [Related]
26. Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience.
Mostafa MYA; Zakaly HMH; Tekin HO; Issa SAM; Erdemir RU; Zhukovsky M
Appl Radiat Isot; 2021 Oct; 176():109841. PubMed ID: 34214913
[TBL] [Abstract][Full Text] [Related]
27. Fast voxel-level dosimetry for (177)Lu labelled peptide treatments.
Hippeläinen E; Tenhunen M; Sohlberg A
Phys Med Biol; 2015 Sep; 60(17):6685-700. PubMed ID: 26270032
[TBL] [Abstract][Full Text] [Related]
28. 4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET.
Walrand S; Jamar F; van Elmbt L; Lhommel R; Bekonde EB; Pauwels S
J Nucl Med; 2010 Dec; 51(12):1969-73. PubMed ID: 21078802
[TBL] [Abstract][Full Text] [Related]
29. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
30. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
31. Monte Carlo and experimental internal radionuclide dosimetry in RANDO head phantom.
Ghahraman Asl R; Nasseri S; Parach AA; Zakavi SR; Momennezhad M; Davenport D
Australas Phys Eng Sci Med; 2015 Sep; 38(3):465-72. PubMed ID: 26232251
[TBL] [Abstract][Full Text] [Related]
32. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
[TBL] [Abstract][Full Text] [Related]
33. 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT.
Gosewisch A; Ilhan H; Tattenberg S; Mairani A; Parodi K; Brosch J; Kaiser L; Gildehaus FJ; Todica A; Ziegler S; Bartenstein P; Böning G
EJNMMI Res; 2019 Aug; 9(1):76. PubMed ID: 31414241
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
35. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
36. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
37. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
Fisher DR; Shen S; Meredith RF
J Nucl Med; 2009 Apr; 50(4):644-52. PubMed ID: 19289440
[TBL] [Abstract][Full Text] [Related]
38. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
Breitz HB; Fisher DR; Wessels BW
J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
[TBL] [Abstract][Full Text] [Related]
39. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
40. Preliminary dosimetric evaluation of (166)Ho-TTHMP for human based on biodistribution data in rats.
Yousefnia H; Zolghadri S; Jalilian AR; Tajik M; Ghannadi-Maragheh M
Appl Radiat Isot; 2014 Dec; 94():260-265. PubMed ID: 25255303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
